Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.36 |
| ▸ | PYGL | P06737 | 3/20 | 0.36 |
| ▸ | PYGM | P11217 | 2/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18537499 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL3412930 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL21539187 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL13559216 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL18681231 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL12658343 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL16918679 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL12899851 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL13787598 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL12929272 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042660-A2 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | RFS Pharma, LLC. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20140113880-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-8637475-B1 | Modified 2′ and 3′ nucleoside prodrugs for treating flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637475-B1 | Modified 2′ and 3′ nucleoside prodrugs for treating flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130149283-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130149283-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130017171-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-01-17 | — | — | US | disclosed |
| US-8343937-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-7192936-B2 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070042991-A1 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | IDENIX PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070042939-A1 | Hepatitis C; antivirals; 8-modified,1', 2', 3' or 4'-branched purine nucleoside; treating HCV infection | IDENIX PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070037773-A1 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070032449-A1 | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070027066-A1 | 2' and/or 3' prodrug of 6-modified, 1', 2', 3' or 4'-branched pyrimidine nucleoside for the treatment of a Flaviviridae infection, such as a hepatitis C virus infection; 3'-L-valine ester of .beta.-D-2',6-dimethyl-cytidine; Flaviviridae polymerase inhibitors; low toxicity to host | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7169766-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157441-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032449-A1 | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | PNP, UGT1A3, SLC29A2 | PYGB 1752/4885PYGL 70/4885PYGM 727/4885 |
| US-20070027066-A1 | 2' and/or 3' prodrug of 6-modified, 1', 2', 3' or 4'-branched pyrimidine nucleoside for the treatment of a Flaviviridae infection, such as a hepatitis C virus infection; 3'-L-valine ester of .beta.-D-2',6-dimethyl-cytidine; Flaviviridae polymerase inhibitors; low toxicity to host | DCTD, DIMT1, CYP2D6 | PYGB 3352/4885PYGL 165/4885PYGM 1663/4885 |
| US-20070042991-A1 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | HAVCR2, UGT1A3, UGT1A1 | PYGB 2040/4885PYGL 28/4885PYGM 916/4885 |
| US-20140113880-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | PYGB 1752/4885PYGL 70/4885PYGM 727/4885 |
| US-20130149283-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | PYGB 1780/4885PYGL 3/4885PYGM 198/4885 |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, UGT1A3, SLC29A2 | PYGB 1752/4885PYGL 70/4885PYGM 727/4885 |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | PYGB 1260/4885PYGL 53/4885PYGM 411/4885 |
| US-20070037773-A1 | Methods and compositions for treating flaviviruses and pestiviruses | MTAP, PHOSPHO1, PNP | PYGB 336/4885PYGL 218/4885PYGM 462/4885 |
| US-20130017171-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | PYGB 1780/4885PYGL 3/4885PYGM 198/4885 |
| US-20070042939-A1 | Hepatitis C; antivirals; 8-modified,1', 2', 3' or 4'-branched purine nucleoside; treating HCV infection | PNP, SLC28A1, SLC29A1 | PYGB 2309/4885PYGL 56/4885PYGM 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.